Medical Oncology

, Volume 29, Issue 2, pp 1073–1076 | Cite as

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

  • Grzegorz Helbig
  • Marek Hus
  • Magdalena Hałasz
  • Marek Dudziński
  • Agnieszka Więcławek
  • Małgorzata Stachowicz
  • Anna Soja
  • Sławomira Kyrcz-Krzemień
Original Paper

Abstract

The idiopathic hypereosinophilic syndrome (HES) comprises a heterogenous group of disorders characterized by marked blood eosinophilia with eosinophilia-associated organ damage. Eight patients with a median age at diagnosis of 42 years (range 19–67) received imatinib mesylate (IM) for FIP1L1-PDGFRα-negative HES resistant to previous conventional treatment. Median number of prior therapies was 3 (range 2–4). Median time from diagnosis to IM initiation was 112 months (range 2–293). Four patients were treated daily with 100 mg IM, whereas the remaining four patients were treated daily with 400 mg IM. Four male patients (50%) achieved complete haematologic response (CHR) after median of 7 days (range 3–150) using 100 mg daily IM (n = 2) and 400 mg (n = 2). Median duration of IM treatment for IM responders was 18 months (range 2–88). No adverse events were reported throughout the treatment duration. Two patients maintained CHR while on 100 mg weekly IM. Four patients (2 men and 2 women) failed IM treatment. Median duration of IM for non-responding patients was 3 weeks (range 3–12). Non-responding HES patients were significantly older and had lower percentage of blood eosinophilia when compared with IM responders. Our results suggest that IM, even at lower than conventional doses, may induce and maintain long-term remission for FIP1L1-PDGFRα-negative HES.

Keywords

Imatinib FIP1L1-PDGFRα Hypereosinophilic syndrome 

References

  1. 1.
    Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1–27.CrossRefGoogle Scholar
  2. 2.
    Klion A. How I treat hypereosinophilic syndrome. Blood. 2009;114:3736–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Eng J Med. 2003;348:1201–14.CrossRefGoogle Scholar
  4. 4.
    Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification and management. Blood. 2004;103:2879–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Leuk Res. 2009;33:1127–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92:1173–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica. 2009;94:1236–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Brit J Haematol. 2008;141:200–4.CrossRefGoogle Scholar
  9. 9.
    Metzgeroth G, Walc Z, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukemia and hypereosinophilic syndrome-a phase II study. Brit J Haematol. 2008;143:707–15.CrossRefGoogle Scholar
  10. 10.
    Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status. Leuk Res. 2009;33:837–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusions genes in chronic eosinophilic leukaemia. Brit J Haematol. 2007;138:77–81.CrossRefGoogle Scholar
  12. 12.
    Intermesoli T, Delaini F, Acerboni S, et al. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Brit J Haematol. 2009;147:681–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Grzegorz Helbig
    • 1
  • Marek Hus
    • 2
  • Magdalena Hałasz
    • 3
  • Marek Dudziński
    • 3
  • Agnieszka Więcławek
    • 1
  • Małgorzata Stachowicz
    • 1
  • Anna Soja
    • 1
  • Sławomira Kyrcz-Krzemień
    • 1
  1. 1.Department of Haematology and Bone Marrow TransplantationSilesian Medical UniversityKatowicePoland
  2. 2.Department of Haematology and Bone Marrow TransplantationMedical UniversityLublinPoland
  3. 3.Department of HaematologyProvincial HospitalRzeszówPoland

Personalised recommendations